Anti-CDH17 CAR-T cells infusion
BG-CT-22-013
Phase 1 mab active
Quick answer
Anti-CDH17 CAR-T cells infusion for CDH17-positive Advanced Solid Tumors is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- CDH17-positive Advanced Solid Tumors
- Phase
- Phase 1
- Modality
- mab
- Status
- active